---
title : ë¬´ì œíŒŒì¼
creation_date : 22.11.23
last_modified :
note_type : basic
category :
memo_level :
aliases : 
tags : []
---

Parent : [[_KnowledgeParticle]]
Drived from : [[22.11.23]]

1. Large scale -> small scale -> current status ì‹ìœ¼ë¡œ ê°€ì•¼ê² ë‹¤
	1. ì¼ë‹¨ í•„ìˆ˜ë‚´ìš©ë¶€í„°
		1. Historical backgound
		2. Causative organism
		3. Molecular biology and pathogens
		4. Diagnosis
		5. Epidemiology
		6. symptoms
		7. treatment and prevention
		8. Current situations
		9. Conclusion

ìˆœì„œ ì¡°ì •
1. Historical background
	1. í•œêµ­ì „ìŸ (1950~53)
		1. ì´í˜¸ì™•ë°•ì‚¬ì˜ ë°œë³‘ì›ì¸ ë°”ì´ëŸ¬ìŠ¤ ë³´ê³  (1980ë…„ëŒ€ ì´ˆ)
		2. ìì—°ì ì¸ reservoir(ë³‘ì›ë³´ìœ ì²´)ì¸ ë“¤ì¥(*Apodemus agrarius*)ì˜ íì—ì„œ ë¶„ë¦¬
		3. Hantaanvirusë¡œ ë³´ê³ ë˜ì—ˆìœ¼ë‚˜, ì‹œê°„ì´ ì§€ë‚˜ë©° hantavirusë¡œ ë¶ˆë¦¼
	2. í´ë€ë“œì—ì„œë„ ë°œê²¬ (1980)
		1. ë¶ìœ ëŸ½ì§€ì—­ì— Nephropathia epidemica(NE)ë¼ê³  ì•Œë ¤ì§„ ì•½í•œ HRFSê°€ 1930ë…„ëŒ€ë¶€í„° ì•Œë ¤ì ¸ ìˆì—ˆìŒ 
		2. ì´ ì§ˆë³‘ì˜ ì›ì¸ ë°”ì´ëŸ¬ìŠ¤ëŠ” Puumala virus(PUUV)ë¡œ 1980ë…„ì— ë°œê²¬ë˜ì—ˆìŒ
	4. ë¯¸êµ­ì—ì„œì˜ HCPSì˜ ë°œë³‘(1993)
		1. 1993ë…„ ë¯¸êµ­ì—ì„œ Hantavirus cardiopulmonart syndrome(HCPS)ë¡œ ì•Œë ¤ì§„ ì§ˆë³‘ì´ ë°œìƒí•¨
		2. HCPSì˜ ì›ì¸ ë°”ì´ëŸ¬ìŠ¤ëŠ” Sin Nombre virus(SNV), Andes virus(ANDV)ë¼ê³  ë³´ê³ ë˜ì—ˆìŒ.
	5. HRFSì™€ HCPSì˜ ë¶„ë¦¬
		1. ë³‘ë¦¬í•™ì  íŠ¹ì§• (ì•„ë§ˆ ì´ë¶€ë¶„ì´ ì•„ë‹ˆë¼ ì¢€ í›„ìˆ í•´ì•¼í• ë“¯)
			1. ì´  ì§ˆë³‘ì˜ ì¹˜ì‚¬ìœ¨ì€ 12%(HFRS)ì—ì„œ 40%(HCPS)ì„.
			2. HFRSëŠ” ì‹ ë¶€ì „ê³¼ ì ìƒì¶œí˜ˆë¶€í„° ì‹¬ê°í•œ ë‚´ì¶œí˜ˆê¹Œì§€ ë‹¤ì–‘í•œ ì¶œí˜ˆì„± ì§•í›„ê°€ íŠ¹ì§•ì´ê³ 
			3. HCPSëŠ” ì‹¬íê¸°ëŠ¥ì¥ì• ë¥¼ íŠ¹ì§•ì„
			4. ë‘˜ì´ ê³µí†µì ìœ¼ë¡œ ë¯¸ì„¸í˜ˆê´€ ë‚´í”¼ì˜ íˆ¬ê³¼ì„± ì¦ê°€ë¥¼ ì¼ìœ¼í‚´
			5. í•œíƒ€ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ì— ì˜í•œ ì¦ìƒì€ ì„¸í¬ë³‘ë¦¬í•™ì ì¸ ì´ìœ ë¡œ ë°œìƒí•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì¸ê°„ì˜ ë©´ì—­ì²´ê³„ê°€ ì¤‘ìš”í•œ ì—­í• ì„ í•˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì„
			6. ë‘˜ ëª¨ë‘ ê¸‰ì„± ë°œì—´ì¦ìƒì„ ë³´ì´ëŠ”ë°, ì¼ë°˜ì ìœ¼ë¡œ ì„¤ì¹˜ë¥˜ì˜ ë¶„ë³€/ë¶„ë¹„ë¬¼ì— í¬í•¨ëœ ë°”ì´ëŸ¬ìŠ¤ì— ì˜¤ì—¼ëœ ì—ì–´ë¡œì¡¸ì´ë‚˜ ë¨¼ì§€ë¥¼ í¡ì…í•´ì„œ ë°œìƒí•¨.
	6. ê¸°íƒ€ ë‚´ìš© 
		1. ê·¹ë™ëŸ¬ì‹œì•„ í‘ë£¡ê°•(ì•„ë¬´ë¥´) ì£¼ë³€ì—ì„œì˜ ë°œë³‘ê¸°ë¡ì´ ìˆìŒ
2. Epidemiology (and ecology)
	1. ![[Pasted image 20221123144605.png]]
		1. í•œíƒ€ë°”ì´ëŸ¬ìŠ¤ì†ì— ìˆëŠ” ë°”ì´ëŸ¬ìŠ¤ë“¤ì˜ ë³‘ì›ë³´ìœ ìë“¤
	2. ![[Pasted image 20221123144746.png]]
		1. ì „ì—¼ë§¤ì»¤ë‹ˆì¦˜
			1. Person-to-person transmission was considered unlikely until 1996, when reports regarding transmission of ANDV in an HCPS outbreak in Argentina changed this perception
			2. ì‚¬ëŒ ê°„ ì „íŒŒëŠ” 1996ë…„ ì•„ë¥´í—¨í‹°ë‚˜ì—ì„œ ë°œìƒí•œ HCPS ë°œë°œì—ì„œ ANDVì˜ ì „íŒŒì— ê´€í•œ ë³´ê³ ì„œê°€ ì´ëŸ¬í•œ ì¸ì‹ì„ ë°”ê¿€ ë•Œê¹Œì§€ ê°€ëŠ¥ì„±ì´ ì—†ëŠ” ê²ƒìœ¼ë¡œ ê°„ì£¼ë˜ì—ˆìŠµë‹ˆë‹¤.
	3. ![[Pasted image 20221123165600.png]]
		1. Epidemiology of hantavirus infections in Europe. Incidence for hantavirus infection in **2019** as recorded by the European Centre for Disease Prevention and Control (ECDC).
	4. ![[Pasted image 20221123172413.png]] (2010)
3. Causative organism
	1. ![[Pasted image 20221123145042.png]]
		1. Several hantaviruses that have been demonstrated to circulate in Europe and Asia belong to the so-called â€˜Old World hantavirusesâ€™
		2. A second group of hantaviruses are so-called â€˜New World hantavirusâ€™, which were first recognized in 1993, after an outbreak of an acute pulmonary distress syndrome in America.
4. Molecular biology and pathogens
	1. Viral genome
		1. ![[Pasted image 20221123163844.png]]
			1. The genome comprises three negativesense, single-stranded RNAs that share a 30 terminal sequence of the genome segments. The three segments, S (small), M (medium) and L (large), encode the nucleoprotein (N), envelope glycoproteins (Gn and Gc), and the L protein or viral RNA-depended RNA polymerase, respectively [9].
			2. The genome comprises **three negativesense**, **single-stranded RNAs**
				1. S ; nucleoprotein (N)
				2. M ; envelope glycoproteins (Gn and Gc)
				3. L ; L protein or viral RNA-depended RNA polymerase(RdRp)
			3. Like other enveloped viruses, hantaviruses are readily inactivated by heat (30 min at 60C), detergents, UV irradiation, organic solvents and hypochlorite solutions.
			4. Hantaviruses infect endothelial, epithelial, dendritic and lymphocyte cells by the attachment of the viral glycoprotein to the cell surface receptors.
				1. it is considered that [[Î²1-integrin]] interacts with viral Gn of apathogenic hantaviruses, while [[Î²3-integrin]] interacts with the glycoprotein of pathogenic hantaviruses
	2. Infection mechanism
		1. ![[Pasted image 20221123163800.png]]
		2. Hantaviruses infect endothelial, epithelial, dendritic and lymphocyte cells by the attachment of the viral glycoprotein to the cell surface receptors.
			1. it is considered that [[Î²1-integrin]] interacts with viral Gn of apathogenic hantaviruses, while [[Î²3-integrin]] interacts with the glycoprotein of pathogenic hantaviruses
		3. Hantaviruses replicate in the cytoplasm and the glycoproteins are targeted to the Golgi complex, where most hantaviruses bud.
			1. However, SNV(Sin Nombre virus) has been shown to bud at the plasma membrane.
	3. Pathogenesis
		1. ![[Pasted image 20221123173446.png]]
			1. vascular endothelial growth factors (VEGF) ; í˜ˆê´€ë‚´í”¼ì„±ì¥ì¸ì
			2. bradykinin and cytokines
				1. ë¸Œë˜ë””í‚¤ë‹Œì€ ëª¨ì„¸í˜ˆê´€ì˜ íˆ¬ê³¼ì„±ì„ ì¦ê°€ì‹œì¼œ ë°±í˜ˆêµ¬ì˜ ìœ ì¶œì„ ì¼ìœ¼í‚¤ëŠ” ìƒë¦¬í™œì„±í©í‹°ë“œì´ë‹¤. í‰í™œê·¼ì„ ì²œì²œíˆ ìˆ˜ì¶•ì‹œí‚¤ëŠ” ì‘ìš©ì´ ìˆê¸° ë•Œë¬¸ì— brady + kininì´ë¼ê³  ëª…ëª…í•˜ì˜€ë‹¤.
			3. thrombocytopenia; í˜ˆì†ŒíŒ ê°ì†Œì¦
			4. Coagulation; ì‘ê³ 
		2. HFRS and HCPS have an overlapping pathophysiology consisting of increased vascular permeability(í˜ˆê´€íˆ¬ê³¼ì„±), platelet activation(í˜ˆì†ŒíŒ í™œì„±í™”) and an overreacting host immune response(ë©´ì—­ê³¼ë¯¼)
			1. Differences in disease are reflected by the different vascular beds that are primarily infectedâ€”renal medulla or pulmonary capillaries. However, the mechanisms mediating cell tropism and organ-specific dysfunction during HFRS and HCPS remain unknown
				1. HFRSì™€ HCPSì˜ ì°¨ì´ëŠ” ì„œë¡œ ë‹¤ë¥¸ í˜ˆê´€ìƒì— ê°ì—¼ëœë‹¤ëŠ” ê²ƒì— ì˜í•´ ë°œìƒí•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì´ ë‘˜ì´ ì–´ë–»ê²Œ ì¥ê¸°ì— íŠ¹ì´ì ìœ¼ë¡œ ì‘ìš©í•˜ëŠ”ì§€ëŠ” ì•Œë ¤ì§€ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.
		3. The pathophysiology of capillary leakage is characterized by the disruption of endothelial cellâ€“cell contacts.
			1. Hantaviruses primarily infect and replicate in endothelial cells of capillaries; í•œíƒ€ë°”ì´ëŸ¬ìŠ¤ëŠ” ëª¨ì„¸í˜ˆê´€ ë‚´ë§‰ì—ì„œ 1ì°¨ê°ì—¼ì„ ì¼ìœ¼í‚¤ê³  ë³µì œë©ë‹ˆë‹¤.
			2. however, there are few to no direct cytopathic effects to the endothelium as detected in histological samples; í•˜ì§€ë§Œ ì„¸í¬ë³‘ë¦¬í•™ì ì¸ íš¨ê³¼ëŠ” ì•„ì£¼ ì ê±°ë‚˜ ì—†ìŠµë‹ˆë‹¤.
		4. it is hypothesized that the breakdown of endothelial cell-to-cell contact is mainly caused by the release of vasoactive factors **rather than endothelial cell death**
		5. Interestingly, the ability of hantaviruses to infect endothelial cells is shared with many (emerging) viruses
			1. Hence dysregulation in vascular function contributes significantly to pathophysiology in many life-threatening viral infections and our growing knowledge due to the current coronavirus disease 2019 (COVID-19) pandemic may promote research advances for hantavirus disease
		6. In NE patients the cytotoxic T-lymphocyte response enhanced the number of activated CD8Ã¾ T cells and reversed CD4Ã¾ versus CD8Ã¾ T-cell ratio, which coincides with the onset of clinical disease
		7. A mixed pattern of T helper type 1 and T helper type 2 immune response patterns, high levels of proinflammatory cytokines and their insufficient suppression by regulatory cytokines leads to the harmful effect of immune response in HFRS-infected patients
5. Symptoms (ë³‘ë¦¬í•™ì  íŠ¹ì§•?)
	1. ![[Pasted image 20221123144027.png]]
	2. A typical course of haemorrhagic fever with renal syndrome (HFRS)
		1. Incubation period (ì ë³µê¸°)
		2. Febrile phase (ë°œì—´ê¸°)
		3. Hypotensive (ì €í˜ˆì••)
		4. Oliguric (í•ë‡¨ê¸°)
		5. Polyuric (ë‹¤ë‡¨ê¸°)
		6. Convalescent (íšŒë³µê¸°)
	3. ì´  ì§ˆë³‘ì˜ ì¹˜ì‚¬ìœ¨ì€ 12%(HFRS)ì—ì„œ 40%(HCPS)ì„.
	4. HFRS is characterized by renal failure and haemorrhagic manifestations that vary from petechiae to severe internal bleeding.; HFRSëŠ” ì‹ ë¶€ì „ê³¼ ì ìƒì¶œí˜ˆë¶€í„° ì‹¬ê°í•œ ë‚´ì¶œí˜ˆê¹Œì§€ ë‹¤ì–‘í•œ ì¶œí˜ˆì„± ì§•í›„ê°€ íŠ¹ì§•ì´ê³ 
	5. Pneumonia and cardiovascular dysfunction are characteristics of HCPS.; HCPSëŠ” ì‹¬íê¸°ëŠ¥ì¥ì•  íŠ¹ì§•ì„
	6. Increased permeability of microvascular endothelium seems to be a common effect of hantavirus infection.; ë‘˜ì´ ê³µí†µì ìœ¼ë¡œ ë¯¸ì„¸í˜ˆê´€ ë‚´í”¼ì˜ íˆ¬ê³¼ì„± ì¦ê°€ë¥¼ ì¼ìœ¼í‚´
	7. í•œíƒ€ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ì— ì˜í•œ ì¦ìƒì€ ì„¸í¬ë³‘ë¦¬í•™ì ì¸ ì´ìœ ë¡œ ë°œìƒí•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì¸ê°„ì˜ ë©´ì—­ì²´ê³„ê°€ ì¤‘ìš”í•œ ì—­í• ì„ í•˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì„
	8. 
6. Diagnosis
	1. The diagnosis of HFRS and HCPS is based on **clinical and epidemiological data** and **laboratory tests.**
		1. However, it is almost impossible to diagnose hantavirus infections solely on clinical grounds, especially in cases with mild and moderate clinical symptoms, as the early signs of the disease are non-specific.
	2. Laboratory diagnosis of acute hantavirus infections is based on serology as virtually all patients have IgM and usually also IgG antibodies present in serum at the onset of symptoms.
		1. ELISA
		2. detection of hantavirus genome in blood or serum samples by RT-PCR.
			1. In addition, with detection of viral RNA, hantavirus infection has been confirmed even before the presence of specific antibodies
		
7. Treatment and prevention
	1. Treatment
		1. At present, no specific U.S. Food and Drug Administrationapproved therapy is available for either HFRS or HCPS
			1. the treatment is primarily supportive. It is recommended that patients with HCPS and severe HFRS should be moved to an intensive care unit for close monitoring and care.
	2. Prevention
		1. Caution
			1. One of the major risk factors for infection is living close to forested areas and cleaning up around houses or sheds.
				1. In addition, occupational exposures, such as construction or forest workers, farmers and soldiers are at increased risk
			2. The preventive measures are based mainly on rodent control, reducing rodents' shelter and food sources near human housing, eliminating rodents inside homes and avoiding contact with potentially contaminated areas.
		2. Vaccine
			1. the only way of minimizing the risk of hantavirus disease could be effective vaccines, but up to now no vaccines were approved for wide use in Europe or the USA.
			2. In Asia, the **Republic of Korea**, HantavaxÂ® has been used for a number of years. The vaccine is derived from **formalin-inactivated HTNV-infected suckling mouse brain**, but frequent booster doses are needed for protective immunity
			3. In **China**, several different **formalininactivated vaccines from animal tissues** have been produced and used, but none has been approved for use in European countries.
			4. Apart from that, only two molecular vaccines against HFRS have been tested in humans, the first was recombinant **vaccinia-vectored vaccine** expressing the **M segment of HTNV** and **the second plasmid DNA.**
8. Current situations
	1. Global
	2. êµ­ë‚´(ë™ì•„ì‹œì•„)
		1. ![[Pasted image 20221123143058.png]]
9. Conclusion